

Table S1 Comparison of clinicopathological characteristics of malignant lesions between the low-risk and high-risk groups

| | Low risk, n (%) | High risk, n (%) | P value |
|-------------------|-----------------|------------------|---------|
| Molecular subtype | | | |
| ER+ & HER2- | 14 (36.8) | 24 (63.2) | 0.939 |
| ER+ & HER2+ | 1 (25.0) | 3 (75.0) | |
| ER- & HER2+ | 0 (0) | 1 (100) | |
| Triple negative | 3 (42.9) | 4 (57.1) | |
| Histological type | | | |
| IDC | 9 (34.6) | 17 (65.4) | 0.956 |
| ILC | 0 (0) | 1 (100) | |
| DCIS | 6 (40.0) | 9 (60.0) | |
| Others | 4 (40.0) | 6 (60.0) | |
| Ki67 | | | |
| <15 | 13 (34.2) | 25 (65.8) | 0.735 |
| ≥15 | 5 (41.7) | 7 (58.3) | |

IDC, invasive ductal carcinoma; DCIS, ductal carcinoma *in situ*; ILC, invasive lobular carcinoma; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.